Beyond Croup: A Phenotype-Based Perspective on Parainfluenza Virus Types in Children

Human parainfluenza viruses (PIVs) caused an estimated 18.8 million acute lower respiratory infection episodes, 725 000 hospitalizations, and 34 400 deaths among children under 5 in 2018, ranking second only to respiratory syncytial virus (RSV). Despite this burden, clinical attention has historically focused on croup, leading to the common perception that parainfluenza is a single disease entity. However, the 4 types differ substantially in taxonomy, tropism, clinical syndrome, and severity. PIV-1, the most common cause of croup, drives biennial epidemics in toddlers, whereas PIV-2 is less frequent but can cause severe disease, particularly in children with underlying conditions. PIV-3 predominates in young infants, causing bronchiolitis and pneumonia clinically like RSV infection, reflecting its early postnatal susceptibility, which may relate to earlier and more frequent viral exposure. PIV-4, historically underrecognized due to culture limitations, usually does not cause croup but is linked to lower respiratory tract disease, hypoxemia, and occasional neurologic complications. PIV infections are most severe in infants, immunocompromised children, and those in low-resource settings. Seasonal patterns vary by type and geography. Advances in multiplex molecular diagnostics now allow rapid type-specific detection, improving clinical interpretation and management. No vaccine or antiviral is licensed. Emerging therapeutics include sialidase-based antivirals with Food and Drug Administration Breakthrough designation; monoclonal antibodies capable of cross-neutralizing PIV-1, PIV-3, RSV, and human metapneumovirus; and messenger RNA vaccines showing early immunogenicity in children. Recognizing the distinct epidemiology, clinical features, and immune responses of each type is critical for informed pediatric care and the development of targeted preventive and therapeutic strategies.